Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers show that a two-step personalized immunotherapy treatment -- a dendritic cell vaccine using patients' own tumor followed by adoptive T cell therapy -- triggers anti-tumor immune responses in these type of patients.